Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
Latest Information Update: 19 Jul 2023
At a glance
- Drugs BZDS 1901 (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Cell Therapy Group
- 13 Jul 2023 Planned End Date changed from 30 Oct 2023 to 30 Jan 2025.
- 13 Jul 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Jul 2024.
- 13 Jul 2023 Status changed from not yet recruiting to recruiting.